Valuation: Veloxis Pharmaceuticals A/S

Market Cap 1.05TCr 7.12TCr 952.32Cr 877.51Cr 798.21Cr 1.5TCr 97TCr 1.57TCr 11TCr 4.24TCr 53TCr 3.92TCr 3.84TCr 1,66000Cr P/E 2017
-154x
P/E 2018 -708x
Enterprise Value 1.05TCr 7.14TCr 954.99Cr 879.97Cr 800.45Cr 1.5TCr 97TCr 1.58TCr 11TCr 4.26TCr 53TCr 3.93TCr 3.85TCr 1,66400Cr EV / Sales 2017
49.4x
EV / Sales 2018 95.8x
Free-Float
10%
Yield 2017 *
-
Yield 2018 -
30/24/30 Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia CI
28/22/28 Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) CI
26/21/26 Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA. CI
17/20/17 Veloxis Pharmaceuticals A/S Announces Board Appointments CI
07/20/07 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index CI
30/20/30 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
30/20/30 Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index CI
14/20/14 Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others. CI
25/19/25 Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/19/25 Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion. CI
13/19/13 Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/19/12 Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
31/19/31 Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019 CI
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 13/09/2017
Chief Operating Officer - 01/03/2016
Director TitleAgeSince
Chairman - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 164.41Cr
-0.30%-6.68%+27.12%+127.32% 1,20000Cr
+1.25%-5.35%+32.65%+78.98% 65TCr
+0.94%-2.99%+21.13%+106.30% 51TCr
-0.60%-1.95%+25.73%+67.00% 38TCr
+0.69%-9.50%+36.78%+30.83% 33TCr
+0.41%-4.70%+24.18%+50.18% 29TCr
+0.81%-4.08%-2.95%+31.59% 27TCr
-0.15%-6.45%+29.06%+65.76% 24TCr
-0.06%-0.98%+31.42%+122.83% 21TCr
Average +0.30%-4.28%+25.01%+75.64% 41TCr
Weighted average by Cap. +0.30%-5.19%+26.02%+87.88%

Financials

2017 2018
Net sales 3.02Cr 21Cr 2.75Cr 2.53Cr 2.3Cr 4.32Cr 279.35Cr 4.54Cr 31Cr 12Cr 152.58Cr 11Cr 11Cr 478.85Cr 3.95Cr 27Cr 3.6Cr 3.31Cr 3.02Cr 5.66Cr 365.71Cr 5.94Cr 40Cr 16Cr 199.75Cr 15Cr 15Cr 626.9Cr
Net income -95.42L -6.49Cr -86.91L -80.08L -72.84L -1.37Cr -88Cr -1.44Cr -9.75Cr -3.87Cr -48Cr -3.58Cr -3.5Cr -151.46Cr -52.85L -3.6Cr -48.14L -44.35L -40.35L -75.69L -49Cr -79.55L -5.4Cr -2.15Cr -27Cr -1.98Cr -1.94Cr -84Cr
Net Debt 1.81Cr 12Cr 1.64Cr 1.52Cr 1.38Cr 2.59Cr 167.16Cr 2.72Cr 18Cr 7.33Cr 91Cr 6.77Cr 6.63Cr 286.55Cr 2.94Cr 20Cr 2.68Cr 2.47Cr 2.24Cr 4.21Cr 272.11Cr 4.42Cr 30Cr 12Cr 148.62Cr 11Cr 11Cr 466.44Cr
Logo Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Company’s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Company’s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.
Employees
-
  1. Stock Market
  2. Stocks
  3. VELO Stock